Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjectsSreeneeranj Kasichayanula, David W. Boulton, W. C. Shyu et al.|Diabetes Obesity and Metabolism|2010Cited by 90